March 9, 2018 09:43 AM ESTUpdated 10:00 AM
Bioregnum
Opinion

The Mar­tin Shkre­li saga ends to­day, but the is­sue he raised on drug pric­ing seems im­mor­tal

Mar­tin Shkre­li is of­fer­ing us one last les­son to­day on the con­se­quences of crim­i­nal­ly bad be­hav­ior.

A fed­er­al judge, al­ready riled enough by Shkre­li’s de­ci­sion …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times